The effects of combination of ifosfamide,nedaplatin and pharmorubicin in treatment of relapsed ovarian carcinoma
10.3760/cma.j.issn.1008-6706.2010.21.016
- VernacularTitle:异环磷酰胺、表柔比星及奈达铂联合治疗复发性卵巢癌疗效观察
- Author:
Chunxiang QIANG
;
Xiaofang WANG
- Publication Type:Journal Article
- Keywords:
Ovarian neoplasm;
Ifosfamide;
Nedaplatin;
Pharmorubicin
- From:
Chinese Journal of Primary Medicine and Pharmacy
2010;17(21):2913-2914
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the treatment effectsand safety of ifosfamide,nedaplatin with pharmorubicin in relapsed ovarian carcinoma.Methods Sixteen relapsed ovarian carcinoma patients received nedaplatin 150mg in 0.9% sodium chloride 500ml dl,intravenously;pharmorubicin 40mg in 5% glucose 50 ml d1-2,intravenously;and ffosfamide 2.0g in 0.9% sodium chloride 500ml d1-5,intravenously.And the treatment effects and side effects were investigated.Results Of the sixteen patients,one had a complete response,six had a partial response,seven had stable disease,and two had progressive disease.The overall response rate was 43.75%(7/16).The major side effects were bone marrow suppression and gastrointestinal reaction.Conclusion Combination of ffosfamide,nedaplatin and pharmorubicin were very effective in relapsed ovarian carcinoma and the side effects were tolerable.Therefore the regimen is worth promoting in the clinical application.
